# OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

> **NCT01920945** · PHASE2 · TERMINATED · sponsor: **St. Luke's-Roosevelt Hospital Center** · enrollment: 6 (actual)

## Conditions studied

- New Daily Persistent Headache

## Interventions

- **DRUG:** OnabotulinumtoxinA

## Key facts

- **NCT ID:** NCT01920945
- **Lead sponsor:** St. Luke's-Roosevelt Hospital Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Difficult enrollment
- **Last updated:** 2016-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01920945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01920945, "OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01920945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*